WEKO3
アイテム
{"_buckets": {"deposit": "af22b678-531b-49b4-ac50-edf3ae323bfe"}, "_deposit": {"created_by": 11, "id": "3561", "owners": [11], "pid": {"revision_id": 0, "type": "depid", "value": "3561"}, "status": "published"}, "_oai": {"id": "oai:shiga-med.repo.nii.ac.jp:00003561", "sets": ["79"]}, "author_link": ["4010", "675", "674"], "item_4_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2020-01-28", "bibliographicIssueDateType": "Issued"}, "bibliographicPageEnd": "9", "bibliographicPageStart": "1", "bibliographicVolumeNumber": "9", "bibliographic_titles": [{}, {"bibliographic_title": "Journal of Asian Association of Schools of Pharmacy", "bibliographic_titleLang": "en"}]}]}, "item_4_creator_3": {"attribute_name": "著者別名", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "野田, 哲史"}], "nameIdentifiers": [{"nameIdentifier": "674", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "60865707", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=60865707"}]}, {"creatorNames": [{"creatorName": "森田, 真也"}], "nameIdentifiers": [{"nameIdentifier": "4010", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "20449870", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=20449870"}, {"nameIdentifier": "0000-0003-4079-707X", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0003-4079-707X"}]}, {"creatorNames": [{"creatorName": "寺田, 智祐"}], "nameIdentifiers": [{"nameIdentifier": "675", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "10324641", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=10324641"}]}]}, "item_4_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "In Asia, molecular-targeted therapies using tyrosine kinase inhibitors (TKIs) have achieved a significant increase in the overall survival of cancer patients. These agents are mainly administrated orally at a fixed dose, which often causes large interindividual variability of clinical pharmacokinetic and/or pharmacodynamic (PK/PD) parameters. In particular, Asian patients experience more drug toxicity in response to certain TKIs compared to non-Asian patients. This often results in dose reduction or complete termination of treatment, which has initiated efforts to optimize the dosing schedule to improve drug tolerance. To address these issues, therapeutic drug monitoring has been applied in clinical settings. This review article summarizes the pharmacological factors that are known to cause variations in PK/PD parameters, such as genetic polymorphisms of metabolic enzymes and transporters and drug–drug interactions. This review also discusses the possibility of dose individualization in Asian patients during TKI therapy, primarily focusing on sunitinib or pazopanib.", "subitem_description_type": "Abstract"}]}, "item_4_description_42": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"subitem_description": "Journal Article", "subitem_description_type": "Other"}]}, "item_4_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "JSS COLLEGE OF PHARMACY"}]}, "item_4_relation_48": {"attribute_name": "関係URI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "https://www.aaspjournal.org/abstract.php?article_id=6947"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.aaspjournal.org/abstract.php?article_id=6947", "subitem_relation_type_select": "URI"}}]}, "item_4_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2020 The Asian Association of Schools of Pharmacy"}]}, "item_4_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "2286-6493", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "NODA, Satoshi"}], "nameIdentifiers": [{"nameIdentifier": "674", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "60865707", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=60865707"}]}, {"creatorNames": [{"creatorName": "森田, 真也"}], "nameIdentifiers": [{"nameIdentifier": "4010", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "20449870", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=20449870"}, {"nameIdentifier": "0000-0003-4079-707X", "nameIdentifierScheme": "ORCID", "nameIdentifierURI": "https://orcid.org/0000-0003-4079-707X"}]}, {"creatorNames": [{"creatorName": "TERADA, Tomohiro"}], "nameIdentifiers": [{"nameIdentifier": "675", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "10324641", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=10324641"}]}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "tyrosine kinase inhibitors", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "individual dosing", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "therapeutic drug monitoring", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Asians", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Personalized pharmacotherapy with sunitinib and pazopanib for Asian patients.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Personalized pharmacotherapy with sunitinib and pazopanib for Asian patients."}]}, "item_type_id": "4", "owner": "11", "path": ["79"], "permalink_uri": "http://hdl.handle.net/10422/00012682", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-06-01"}, "publish_date": "2020-06-01", "publish_status": "0", "recid": "3561", "relation": {}, "relation_version_is_last": true, "title": ["Personalized pharmacotherapy with sunitinib and pazopanib for Asian patients."], "weko_shared_id": -1}
Personalized pharmacotherapy with sunitinib and pazopanib for Asian patients.
http://hdl.handle.net/10422/00012682
http://hdl.handle.net/10422/000126825521178a-f690-49a4-b2cb-331ec05c2b0d
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-06-01 | |||||
タイトル | ||||||
タイトル | Personalized pharmacotherapy with sunitinib and pazopanib for Asian patients. | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | tyrosine kinase inhibitors | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | individual dosing | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | therapeutic drug monitoring | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Asians | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
NODA, Satoshi
× NODA, Satoshi× 森田, 真也× TERADA, Tomohiro |
|||||
著者別名 |
野田, 哲史
× 野田, 哲史× 森田, 真也× 寺田, 智祐 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | In Asia, molecular-targeted therapies using tyrosine kinase inhibitors (TKIs) have achieved a significant increase in the overall survival of cancer patients. These agents are mainly administrated orally at a fixed dose, which often causes large interindividual variability of clinical pharmacokinetic and/or pharmacodynamic (PK/PD) parameters. In particular, Asian patients experience more drug toxicity in response to certain TKIs compared to non-Asian patients. This often results in dose reduction or complete termination of treatment, which has initiated efforts to optimize the dosing schedule to improve drug tolerance. To address these issues, therapeutic drug monitoring has been applied in clinical settings. This review article summarizes the pharmacological factors that are known to cause variations in PK/PD parameters, such as genetic polymorphisms of metabolic enzymes and transporters and drug–drug interactions. This review also discusses the possibility of dose individualization in Asian patients during TKI therapy, primarily focusing on sunitinib or pazopanib. | |||||
書誌情報 |
en : Journal of Asian Association of Schools of Pharmacy 巻 9, p. 1-9, 発行日 2020-01-28 |
|||||
出版者 | ||||||
出版者 | JSS COLLEGE OF PHARMACY | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 2286-6493 | |||||
権利 | ||||||
権利情報 | © 2020 The Asian Association of Schools of Pharmacy | |||||
資源タイプ | ||||||
内容記述タイプ | Other | |||||
内容記述 | Journal Article | |||||
関係URI | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://www.aaspjournal.org/abstract.php?article_id=6947 | |||||
関連名称 | https://www.aaspjournal.org/abstract.php?article_id=6947 |